Abstract 189P
Background
This study evaluates the local control rates of patients treated with Stereotactic Body Radiotherapy (SBRT) for unresectable primary Hepatocellular carcinoma and oligometastatic liver lesions.
Methods
21 patients with 26 lesions treated with SBRT between February 2015 and March 2018. 3/21(14.2%) patients were primary hepatocellular carcinoma, 2/21(9.4%) were primary cholangiocarcinoma and 16/21(76.1%) patients were metastatic lesions. 16/21 patients had single, 3/21patients had two and 1/21 patient had three lesions. Patients were immobilized with thermoplastic mask with an indigenous abdominal compression device for motion management. Radiation planning triple phase CT scan with slice thickness of 1mm were fused with PET/CT scan and MRI scan. GTV is delineated and ITV is generated based on CT image data set in multiple phases of respiration. Adequate PTV margin was given.2/21(9.4%) patients were treated with IMRT technique, 17/21(79%) were planned with volumetric arc technique and 2/21(9.4%) were treated with helical Tomotherapy. The mean volume of the lesions treated was 31.1cc (Range,1.5cc to 314.9cc). Dose ranged from 18Gy-24Gy in single fraction, 24Gy-54Gy in three fractions and 30Gy-50Gy in 5 fractions. Mean volume of normal liver is 1195cc. Mean dose to 700cc of normal liver was 365.8cGy (Range, 11.7cGy-1428.6cGy). All the patients received different types of systemic therapy also.
Results
The median follow up was 24 months.All 21 patients were evaluable for response based on triple phase computed tomography scan obtained in every 3 months after completion of SBRT. All 5/5(100%) patients of primary HCC and cholangiocarcinoma and 15/16 (93.7%) patients with metastatic lesionswere in radiological complete response at local site at the end of 12 months. Two year local control rate for metastatic lesions was 90%. there was no grade 3 or higher toxicity.
Conclusions
In our series of 21 patients of primary hepatocellular carcinoma and oligometastatic liver lesions excellent local control has been achieved by SBRT with acceptable toxicity.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
437P - Correlation between bio-impedance analysis and abdominal CT scan to diagnose decreased muscle mass in adult cancer patients
Presenter: Andree Kurniawan
Session: Poster display session
Resources:
Abstract
438P - Evaluating mitochondrial biomarkers between fatigue subclasses identified using latent class analysis in early-stage breast cancer patients
Presenter: Yi Long Toh
Session: Poster display session
Resources:
Abstract
440P - Accuracy of risk scoring system to determine delayed chemotherapy induced nausea and vomiting (CINV) in cancer patients
Presenter: Jada Harika
Session: Poster display session
Resources:
Abstract
441P - A pilot cross-sectional study on incidence of liver toxicity in cancer patients on western anti-cancer drug therapy with or without concurrent Chinese herbal medicine
Presenter: Tsz Him So
Session: Poster display session
Resources:
Abstract
442P - Relationship between QOL and support elderly patients with permanent colostomies
Presenter: Yukiko Orii
Session: Poster display session
Resources:
Abstract
443P - The effectiveness of individual nutritional counselling for patients with advanced cancer undergoing chemotherapy: A preliminary study
Presenter: Saori Koshimoto
Session: Poster display session
Resources:
Abstract
444P - The prophylactic effect of 0.1% fluorometholone eye drops on eye disorders caused by high-dose cytarabine
Presenter: Takayuki Tsuchiya
Session: Poster display session
Resources:
Abstract
445P - Safety and feasibility of extending flushing interval every 3 months for maintenance of TICVPS in CRC patients after completion of curative intended treatments
Presenter: Sang Bo Oh
Session: Poster display session
Resources:
Abstract
446P - Accuracy of risk scoring system to determine chemotherapy induced nausea and vomiting (CINV) in cancer patients receiving first cycle chemotherapy
Presenter: Jada Harika
Session: Poster display session
Resources:
Abstract
447P - Hypomagnesaemia: An unnoticed problem in lung cancer patients treated with concurrent chemoradiation
Presenter: Sharif Ahmed
Session: Poster display session
Resources:
Abstract